PDF herunterladen
Semin Liver Dis 2013; 33(S 01): S20-S24
DOI: 10.1055/s-0033-1333633
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Shaping the Future Management of Hepatocellular Carcinoma

Ghassan K. Abou-Alfa
1   Department of Medicine, Memorial Sloan-Kettering Medical Center, Weill Medical College at Cornell University, New York, New York
,
Massimo Colombo
2   1st Division of Gastroenterology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, via F. Sforza 35, Milan, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
01. März 2013 (online)

   Lizenzen und Reprints

Abstract

Several advances in recent years have led to improved surveillance, diagnostic, and treatment options for hepatocellular carcinoma (HCC). Despite these advances, care for this malignancy remains suboptimal, in part because of poor adherence to established guidelines. When diagnosed at an early stage, outcomes for HCC are positive; however, use of appropriate screening techniques and surveillance of at risk patients is still not widely employed. Although a multidisciplinary care team is considered an essential part of successful HCC treatment, fewer than half of the patients with HCC in the United States receive multidisciplinary care. The current suboptimal utilization of potentially curative treatments, including those recommended by treatment guidelines, can be linked to the absence of multidisciplinary care. Additionally, the lack of prognostic and predictive biomarkers for HCC remains challenging, particularly as therapeutic approaches in advanced disease evolve to the use of molecularly targeted agents. Much research is currently focused on the identification of biomarkers for HCC, but improvements in adherence to guidelines for surveillance and appropriate use of available therapies is necessary before care for patients with HCC will improve.

Keywords

hepatocellular carcinoma - HCC biomarkers - liver cancer - multidisciplinary care - HCC surveillance
 

  • References

  • 1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence, Mortality and Prevalence Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. . Available at: http://globocan.iarc.fr/ . Accessed June 6, 2012
    Google Scholar
  • 2 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022. Available at: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf . Accessed July 3, 2012
    PubMedGoogle Scholar
  • 3 Omata M, Lesmana LA, Tateishi R , et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4 (2) 439-474
    CrossrefPubMedGoogle Scholar
  • 4 European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (4) 908-943
    PubMedGoogle Scholar
  • 5 prIME Oncology. Clinical opinion on the treatment of hepatocellular carcinoma. Survey held at: Symposium on Enhancing Clinical Outcomes in Hepatocellular Carcinoma: A Multidisciplinary Expert Practice; November 3, 2011; San Francisco, CA:
  • 6 prIME Oncology. Clinical opinion on the treatment of hepatocellular carcinoma. Survey held at: Symposium on Enhancing Clinical Outcomes in Hepatocellular Carcinoma: A Multidisciplinary Expert Practice; December 3, 2011; Berlin, Germany:
  • 7 Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010; 52 (1) 132-141
    CrossrefPubMedGoogle Scholar
  • 8 Davila JA, Henderson L, Kramer JR , et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011; 154 (2) 85-93
    CrossrefPubMedGoogle Scholar
  • 9 Ye S-L, Takayama T, Geschwind J, Marrero JA, Bronowicki J-P. Current approaches to the treatment of early hepatocellular carcinoma. Oncologist 2010; 15 (Suppl. 04) 34-41
    CrossrefPubMedGoogle Scholar
  • 10 Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer 2011; 117 (5) 1019-1026
    CrossrefPubMedGoogle Scholar
  • 11 Davila JA, Duan Z, McGlynn KA, El-Serag HB. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol 2012; 46 (1) 71-77
    CrossrefPubMedGoogle Scholar
  • 12 El-Serag HB, Siegel AB, Davila JA , et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44 (1) 158-166
    CrossrefPubMedGoogle Scholar
  • 13 Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000; 10 (3) 185-200
    CrossrefPubMedGoogle Scholar
  • 14 Kaposi-Novak P, Libbrecht L, Woo HG , et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 2009; 69 (7) 2775-2782
    CrossrefPubMedGoogle Scholar
  • 15 Llovet JM, Chen Y, Wurmbach E , et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131 (6) 1758-1767
    CrossrefPubMedGoogle Scholar
  • 16 Di Tommaso L, Destro A, Fabbris V , et al. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 2011; 53 (5) 1549-1557
    CrossrefPubMedGoogle Scholar
  • 17 Hoshida Y, Villanueva A, Kobayashi M , et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359 (19) 1995-2004
    CrossrefPubMedGoogle Scholar
  • 18 Nault JC, De Reyniès A, Calderaro J , et al. A molecular signature and algorithm for the diagnosis and prognosis of hepatocellular tumors. Abstract presented at: International Liver Cancer Association Annual Conference; September 2–4, 2011; Hong Kong, China
    PubMedGoogle Scholar
  • 19 Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig Liver Dis 2010; 42 (Suppl. 03) S235-S241
    CrossrefPubMedGoogle Scholar
  • 20 Walther Z, Jain D. Molecular pathology of hepatic neoplasms: classification and clinical significance. Pathol Res Int 2011; 2011: 403929
    PubMedGoogle Scholar
  • 21 Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31 (4) 339-346
    CrossrefPubMedGoogle Scholar
  • 22 de La Coste A, Romagnolo B, Billuart P , et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998; 95 (15) 8847-8851
    CrossrefPubMedGoogle Scholar
  • 23 Miyoshi Y, Iwao K, Nagasawa Y , et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998; 58 (12) 2524-2527
    PubMedGoogle Scholar
  • 24 Laurent-Puig P, Legoix P, Bluteau O , et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120 (7) 1763-1773
    CrossrefPubMedGoogle Scholar
  • 25 Legoix P, Bluteau O, Bayer J , et al. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999; 18 (27) 4044-4046
    CrossrefPubMedGoogle Scholar
  • 26 Audard V, Grimber G, Elie C , et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol 2007; 212 (3) 345-352
    CrossrefPubMedGoogle Scholar
  • 27 Liu J, Yang Y, Zhang H , et al. Longer leukocyte telomere length predicts increased risk of hepatitis B virus-related hepatocellular carcinoma: a case-control analysis. Cancer 2011; 117 (18) 4247-4256
    CrossrefPubMedGoogle Scholar
  • 28 Liu HQ, An JZ, Liu J , et al. Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization. Carcinogenesis 2012; 33 (5) 1040-1045
    CrossrefPubMedGoogle Scholar
  • 29 Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene 2001; 20 (20) 2606-2610
    CrossrefPubMedGoogle Scholar
  • 30 Slamon DJ, Leyland-Jones B, Shak S , et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11) 783-792
    CrossrefPubMedGoogle Scholar
  • 31 Flaherty KT, Puzanov I, Kim KB , et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363 (9) 809-819
    CrossrefPubMedGoogle Scholar
  • 32 Lynch TJ, Bell DW, Sordella R , et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 (21) 2129-2139
    CrossrefPubMedGoogle Scholar
  • 33 Rimassa L, Porta C, Borbath I , et al. Tivantinib (ARQ197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT). J Clin Oncol 2012; 30 (Suppl): Abstract 4006
    PubMedGoogle Scholar